spacer
home > ebr > summer 2003 > losing our minds - what the future holds for the treatment of neurodegenerative disorders
PUBLICATIONS
European Biopharmaceutical Review

Losing Our Minds - What the Future Holds for the Treatment of Neurodegenerative Disorders

The words Alzheimer's or Parkinson's can strike terror in anyone's mind, particularly those of us aged over 50. With the average age of the western world's population rising, a disturbing flipside is that an increasing number of those that enter their 60s and beyond are falling victim to neurodegenerative conditions such as Alzheimer's, Parkinson's and stroke. Billions of dollars have been spent on developing novel effective treatments for these conditions with little success. More importantly, treatments that could actually modify the progress of these diseases rather than merely alleviate some of their symptoms, are urgently required. Demand for new and more effective drugs will therefore continue to intensify. Fortunately, there are now signs of light at the end of the tunnel and the near future could see significant progress in the battle to win back our minds.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Itzchak Angel, Vice President Research and Development at D-Pharm Ltd

Dr Angel joined D-Pharm Ltd, a biopharmaceutical company developing lipid-based drugs for the treatment of central nervous system disorders, cancer and autoimmune diseases, as Vice President of Research & Development in 1998.

He obtained his PhD from the University of Hamburg (1982) and did postdoctoral work at the NIH in the US. Formerly, he was Head of the Pharmacology Department at Synthelabo (France). Dr Angel has over 15 years' experience with preclinical and clinical development programmes in a wide range of therapeutic fields.

spacer
Dr Itzchak Angel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement